KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Non-Current Assets: 2009-2025

Historic Non-Current Assets for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Sep 2025 value amounting to $27.6 million.

  • Rigel Pharmaceuticals' Non-Current Assets fell 16.22% to $27.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.6 million, marking a year-over-year decrease of 16.22%. This contributed to the annual value of $28.9 million for FY2024, which is 60.77% up from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Non-Current Assets stood at $27.6 million, which was down 11.92% from $31.3 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' Non-Current Assets' 5-year high stood at $34.0 million during Q1 2024, with a 5-year trough of $5.2 million in Q3 2022.
  • Its 3-year average for Non-Current Assets is $26.3 million, with a median of $28.9 million in 2024.
  • In the last 5 years, Rigel Pharmaceuticals' Non-Current Assets slumped by 66.47% in 2022 and then surged by 292.73% in 2023.
  • Rigel Pharmaceuticals' Non-Current Assets (Quarterly) stood at $12.9 million in 2021, then surged by 42.88% to $18.4 million in 2022, then fell by 2.27% to $18.0 million in 2023, then skyrocketed by 60.77% to $28.9 million in 2024, then fell by 16.22% to $27.6 million in 2025.
  • Its Non-Current Assets stands at $27.6 million for Q3 2025, versus $31.3 million for Q2 2025 and $29.4 million for Q1 2025.